Breast Neoplasms Clinical Trials

31 studies are recruiting for breast neoplasms in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

   This is a Phase III trial where participants will be randomized to two treatment groups, which means participants will be assigned by equal chance to a treatment group. This trial will be double-blinded, which means neither the participants nor the trial doctors will know which of the two treatment…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Highlands Oncology Group, Springdale, Arkansas

   Locations

   202 in total

   Run by

   BioNTech SE

   See if you can join NCT07173751 on ClinicalTrials.gov

2. ATUSA Ultrasound Diagnostic Imaging for Breast Lesions Evaluation (AUDIBLE) - iSono Health

   AUDIBLE is a multi-site, clinical study conducted in the United States aimed at gathering data on 3D Automated Breast Ultrasound imaging using the iSono Health ATUSA system. The study focuses on female participants who have previously been identified with suspicious findings (classified as BIRADs 4…

   Stage

   Not phased

   Ages

   18 to 94

   Site

   UC Davis, Sacramento, California

   Locations

   2 in total

   Run by

   iSono Health, Inc.

   See if you can join NCT07505797 on ClinicalTrials.gov

3. A Study of Breast Cancer Risk Factors and Outcomes of People in Florida

   The purpose of this study is to understand why different people have different risks and outcomes for breast cancer and non-breast cancer.

   Stage

   Not phased

   Ages

   18 and older

   Site

   University of Miami (Data Collection Only), Miami, Florida

   Locations

   3 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT06780176 on ClinicalTrials.gov

4. Integrating Biological, Clinical, and Behavioral Factors to Improve Breast Cancer Outcomes - Carolina Breast Cancer Study

   Phase 4 of the Carolina Breast Cancer Study (CBCS4) builds on prior phases that examined molecular and epidemiologic differences in breast cancer types and outcomes. Previous findings showed that certain breast cancer subtypes and genetic factors are linked to higher risks. While prior research unc…

   Stage

   Not phased

   Ages

   20 to 74

   Site

   University of North Carolina at Chapel Hill, Chapel Hill, North Carolina

   Run by

   UNC Lineberger Comprehensive Cancer Center

   See if you can join NCT07214610 on ClinicalTrials.gov

5. A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

   Researchers are looking for new ways to treat types of breast cancer that are both: * High-risk, which means the cancer may have a higher chance of getting worse or coming back after treatment * Early-stage, which means the cancer is in the breast or the lymph nodes around the breast The 2 types of…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Banner MD Anderson Cancer Center ( Site 0066), Gilbert, Arizona

   Locations

   325 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT06966700 on ClinicalTrials.gov

6. Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

   Researchers are looking for new ways to treat triple-negative breast cancer (TNBC) and hormone receptor (HR) low positive/human epidermal growth factor receptor-2 (HER2) negative breast cancer. The main goals of this study are to learn: * About the safety of the study treatments and if people toler…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   UCLA Hematology/Oncology - Parkside ( Site 0021), Santa Monica, California

   Locations

   17 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT06797635 on ClinicalTrials.gov

7. Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer

   This is a multi-site, global, open-label study that includes a phase 1b evaluation of elacestrant in combination with abemaciclib in women and men with brain metastases from estrogen receptor (ER)-positive, human epidermal growth factor receptor-2 (HER-2) negative breast cancer. Phase 1b was design…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Providence Medical Foundation, Fullerton, California

   Locations

   86 in total

   Run by

   Stemline Therapeutics, Inc.

   See if you can join NCT05386108 on ClinicalTrials.gov

8. Breast Cancer, Reasoning, and Activity Intervention

   This phase II trial tests whether an exercise intervention works to improve cognitive function in breast cancer survivors. Many breast cancer survivors report cancer-related cognitive impairment, which this has recently become a priority in clinical research due to its dramatic impact on daily func…

   Stage

   Not phased

   Ages

   50 and older

   Site

   Mayo Clinic in Arizona, Phoenix, Arizona

   Run by

   Mayo Clinic

   See if you can join NCT04816006 on ClinicalTrials.gov

9. A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

   The purpose of the study is to assess the efficacy and safety of the addition of Tersolisib (LY4064809/STX-478) to other anti-cancer drugs as first treatment for advanced hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Participants can remain…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Ironwood Cancer & Research Centers, Chandler, Arizona

   Locations

   360 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07174336 on ClinicalTrials.gov

10. A Study of LY4257496 in Participants With Cancer (OMNIRAY)

    The main purpose of this study is to evaluate safety, tolerability, and efficacy of LY4257496 alone and as part of relevant standard of care (SOC) combination therapy in participants with Gastrin-releasing Peptide Receptor (GRPR)-positive advanced cancer, including but not limited to breast, colore…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    City of Hope, Duarte, California

    Locations

    33 in total

    Run by

    Eli Lilly and Company

    See if you can join NCT07114601 on ClinicalTrials.gov

11. A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

    This is a study of LY4337713 in participants with certain types of cancer that is advanced or has spread. Participants must have cancer with high levels of a protein called fibroblast activation protein (FAP). The purpose of this study is to evaluate safety, side effects, and efficacy of LY4337713.…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Hoag Memorial Hospital Presbyterian, Newport Beach, California

    Locations

    30 in total

    Run by

    Eli Lilly and Company

    See if you can join NCT07213791 on ClinicalTrials.gov

12. A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer

    This study will include two groups of patients: Cohort 1 and Cohort 2. Cohort 1: will help researchers learn how a medicine called imlunestrant (LY3484356) affects a specific type of breast cancer. Some patients will take both imlunestrant and another treatment to suppress their ovarian function. S…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana

    Locations

    89 in total

    Run by

    Eli Lilly and Company

    See if you can join NCT07287098 on ClinicalTrials.gov

13. A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

    The purpose of this study is to compare sacituzumab tirumotecan as a single agent, and in combination with pembrolizumab, versus Treatment of Physician's Choice (TPC) in participants with hormone receptor positive/human epidermal growth factor receptor-2 negative (HR+/HER2-) unresectable locally ad…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Ironwood Cancer & Research Centers ( Site 0066), Chandler, Arizona

    Locations

    259 in total

    Run by

    Merck Sharp & Dohme LLC

    See if you can join NCT06312176 on ClinicalTrials.gov

14. Dissemination of BREASTChoice AIM1-B

    This registration covers only Aim 1b, which focuses on testing usability. The study will include 20 participants who are breast cancer patients. Participants will be observed using the tool on their mobile devices, and their experience will be evaluated using a "think-aloud" method to capture their…

    Stage

    Not phased

    Ages

    18 and older

    Site

    The University of North Carolina, Chapel Hill, North Carolina

    Run by

    UNC Lineberger Comprehensive Cancer Center

    See if you can join NCT07396766 on ClinicalTrials.gov

15. Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer

    The purpose of this study is to evaluate the efficacy and safety of ctDNA-guided initiation of CDK4/6 inhibitor therapy using the Signatera™ Designed on Genome test (referred to as "Signatera Genome") in participants with intermediate-risk HR+/HER2- early-stage breast cancer. Based on ctDNA test re…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Stockton Hematology Oncology Medical Group, Stockton, California

    Locations

    49 in total

    Run by

    Natera, Inc.

    See if you can join NCT07214532 on ClinicalTrials.gov

16. A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

    Researchers are looking for other ways to treat breast cancer (BC) that is hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) and either unresectable locally advanced or metastatic. * HR positive (HR+) means the cancer cells have proteins that attach to estr…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Southern Cancer Center (SCC) ( Site 8000), Daphne, Alabama

    Locations

    199 in total

    Run by

    Merck Sharp & Dohme LLC

    See if you can join NCT07060807 on ClinicalTrials.gov

17. PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)

    The goal of this research study is to compare a combination of two drugs, capecitabine and elacestrant to capecitabine alone as a treatment for advanced estrogen receptor-positive (ER+) breast cancer. This study is designed for participants with cancer that has previously stopped responding to medi…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Dana-Farber Cancer Institute, Boston, Massachusetts

    Run by

    Kristina A. Fanucci

    See if you can join NCT07222215 on ClinicalTrials.gov

18. Biennial CEM in Women With a Personal History of Breast Cancer

    This is a prospective clinical trial that will examine if biennial contrast-enhanced mammography added to annual 3D mammography (tomosynthesis) substantially improves breast cancer detection with minimal increase in false-positives, in women with a personal history of breast cancer.

    Stage

    Not phased

    Ages

    30 to 79

    Site

    UPMC Magee-Womens Imaging - Bethel Park, Bethel Park, Pennsylvania

    Locations

    6 in total

    Run by

    Wendie Berg

    See if you can join NCT06105749 on ClinicalTrials.gov

19. A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

    The purpose of this study is to assess the efficacy and safety of iza-bren, a bi-specific antibody-drug conjugate against EGFR and HER3 with a topoisomerase inhibitor payload versus treatment of physician's choice (TPC) (paclitaxel, nab-paclitaxel, carboplatin plus gemcitabine, and capecitabine) fo…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Helios Clinical Research, Cerritos, California

    Locations

    295 in total

    Run by

    Bristol-Myers Squibb

    See if you can join NCT06926868 on ClinicalTrials.gov

20. Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score

    Multiple neoadjuvant endocrine trials demonstrate that women with good prognosis tumors can be identified. These trials have also demonstrated that there are not adverse effects on overall outcome if women are treated with neoadjuvant endocrine therapy for several months prior to definitive treatme…

    Stage

    Phase 2

    Ages

    70 and older

    Site

    Washington University School of Medicine, St Louis, Missouri

    Run by

    Washington University School of Medicine

    See if you can join NCT02476786 on ClinicalTrials.gov

21. A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study

    This is a global extension study to provide continued access to niraparib and further characterize the long-term safety of niraparib treatment in participants who are currently receiving treatment with niraparib within GlaxoSmithKline/TESARO-sponsored studies (NCT01847274, NCT02354586, NCT01905592,…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    GSK Investigational Site, Encinitas, California

    Locations

    25 in total

    Run by

    GlaxoSmithKline

    See if you can join NCT04641247 on ClinicalTrials.gov

22. Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)

    Researchers want to learn if patritumab deruxtecan (MK-1022) can treat certain breast cancers. The breast cancers being studied are HER2 positive unresectable locally advanced or metastatic (the cancer has spread to other parts of the body). The goals of this study are to learn: * About the safety …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Colorado Anschutz Medical Campus ( Site 0057), Aurora, Colorado

    Locations

    18 in total

    Run by

    Merck Sharp & Dohme LLC

    See if you can join NCT06686394 on ClinicalTrials.gov

23. I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

    The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which types of breast cancer tumors and by learning more about which early indicators of response (tumor analysis prior to surgery via magnetic res…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    University of Alabama at Birmingham, Birmingham, Alabama

    Locations

    42 in total

    Run by

    QuantumLeap Healthcare Collaborative

    See if you can join NCT01042379 on ClinicalTrials.gov

24. Tirzepatide Weight Loss for MRD+ Early Breast Cancer

    This trial aims to asses if tirzepatide-induced weight loss will lead to metabolic and hormonal changes in hormone receptor-positive (HR+), human epidermal growth factor receptor-negative (HER2-), node-positive (N+) high risk early breast cancer patients with obesity or overweight, inhibiting the g…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Baylor University Medical Center, Baylor Charles A Sammons Cancer Center, Dallas, Texas

    Run by

    Baylor Research Institute

    See if you can join NCT06517212 on ClinicalTrials.gov

25. A Study of Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer

    Participants will have a sample of their white blood cells, called T cells, collected using a procedure called leukapheresis. The collected T cells will be sent to a laboratory at Memorial Sloan Kettering to be changed (modified) to become MSLN-targeted CAR T cells, the CAR T-cell therapy that part…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey

    Locations

    7 in total

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT06623396 on ClinicalTrials.gov